Drug comparisons
Tirzepatide vs Dapagliflozin
Compare Tirzepatide vs dapagliflozin for T2D. Mounjaro is a dual GIP/GLP-1 agonist for diabetes and weight loss; Farxiga is an SGLT2 inhibitor for T2D, HF, and CKD.
No comparison dimensions are available for this page.
Clinical context
This comparison typically arises for type 2 diabetes patients evaluating incretin-based therapy versus SGLT2 inhibition, especially those with obesity or cardiorenal disease.
Bottom line
Tirzepatide and dapagliflozin offer complementary benefits in type 2 diabetes, with neither universally superior.
All medication comparisons